Innovation, real-world data, and precision medicine

As ASCO 2025 kicks off in Chicago, pharmaphorum looks back to a conversation with Pierre Fabre Laboratories at the ESMO congress last autumn, where we spoke with experts Théodore Leondaridis, Global Franchise Head, Innovative Oncology (Spain); Dr Francesco Hofmann, VP and Head of Research and Development (Switzerland); and Nuria Perez Cullell, Medical Director, Patient & Consumer.

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular focus on lung cancer. From real-world studies to pioneering targeted therapies, Pierre Fabre is positioning itself as a key player in the fight against non-small cell lung cancer (NSCLC).